WallStSmart

MiniMed Group, Inc. Common Stock (MMED)vsTempus AI, Inc. Class A Common Stock (TEM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MiniMed Group, Inc. Common Stock generates 135% more annual revenue ($2.99B vs $1.27B). MMED leads profitability with a -10.7% profit margin vs -19.3%. MMED earns a higher WallStSmart Score of 38/100 (F).

MMED

Hold

38

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 5.0Quality: 5.0

TEM

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 4.0Quality: 5.5
Piotroski: 6/9Altman Z: -2.16
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MMED.

TEMSignificantly Overvalued (-71.3%)

Margin of Safety

-71.3%

Fair Value

$31.29

Current Price

$53.50

$22.21 premium

UndervaluedFair: $31.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MMED1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
15.0%8/10

15.0% revenue growth

TEM1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
83.0%10/10

Revenue surging 83.0% year-over-year

Areas to Watch

MMED4 concerns · Avg: 2.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
-10.7%1/10

Currently unprofitable

Operating MarginProfitability
-11.0%1/10

Operating margin of -11.0%

TEM4 concerns · Avg: 3.0/10
Price/BookValuation
19.4x4/10

Trading at 19.4x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-89.5%2/10

ROE of -89.5% — below average capital efficiency

Free Cash FlowQuality
$-51.78M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MMED

The strongest argument for MMED centers on Revenue Growth. Revenue growth of 15.0% demonstrates continued momentum.

Bull Case : TEM

The strongest argument for TEM centers on Revenue Growth. Revenue growth of 83.0% demonstrates continued momentum.

Bear Case : MMED

The primary concerns for MMED are EPS Growth, Return on Equity, Profit Margin.

Bear Case : TEM

The primary concerns for TEM are Price/Book, EPS Growth, Return on Equity. Debt-to-equity of 2.63 is elevated, increasing financial risk.

Key Dynamics to Monitor

MMED profiles as a turnaround stock while TEM is a hypergrowth play — different risk/reward profiles.

TEM is growing revenue faster at 83.0% — sustainability is the question.

MMED generates stronger free cash flow (13M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MMED scores higher overall (38/100 vs 31/100) and 15.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MiniMed Group, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

Tempus AI, Inc. Class A Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Tempus AI, Inc is a healthcare technology company. The company is headquartered in Chicago, Illinois.

Visit Website →

Want to dig deeper into these stocks?